Pharmaceutical companies are betting on a lesser-known form of cholesterol, Lp(a), to develop potentially blockbuster heart drugs. This shift marks a significant change in how we approach cardiovascular disease and its risk factors.
Historically, the focus has been on LDL cholesterol—the so-called ‘bad’ cholesterol. Doctors and researchers believed that lowering LDL levels would reduce the risk of heart attacks. Yet, studies have shown that this isn’t the whole story. Many patients with normal LDL levels still suffer from cardiovascular issues. So what about Lp(a)?
Lp(a) was first discovered in 1963, but it remained largely under the radar until recently. Research indicates that people with high levels of Lp(a) face more than double the risk of heart attack compared to those without elevated levels. An estimated one in five people worldwide has elevated Lp(a). This alarming statistic is prompting pharmaceutical giants like Novartis, Amgen, and Eli Lilly to explore treatments targeting this specific cholesterol.
The decisive moment came when these companies began late-stage trials for drugs aimed at reducing Lp(a) levels. Novartis’ pelacarsen, for instance, aims to lower Lp(a) significantly. Preliminary data suggests that these experimental drugs can slash levels of Lp(a) by more than 80%. That’s a staggering reduction—one that could reshape cardiology as we know it.
What does this mean for patients? If these drugs prove effective in preventing heart attacks, we might see a new era in cardiovascular treatment. However, uncertainties remain. The exact levels of Lp(a) that need to be lowered to prevent heart attacks are still unclear. Additionally, the timeline for results from Novartis’ trial has been delayed due to slower-than-expected occurrences of heart attacks among participants.
Experts are optimistic about this shift. Dr. Steve Nissen notes the importance of keeping an open mind regarding cholesterol management strategies: “We thought raising HDL would be beneficial and that didn’t work, so I think we have to keep an open mind.” Jay Bradner adds that the clarity from population genetics renders this pursuit a smart bet.
As these companies push forward with their trials, they hope at least one drug will succeed—”We hope at least one of them ends up in the back of the net,” says Dr. Nissen. The stakes couldn’t be higher; with cardiovascular disease being a leading cause of death globally, effective treatments are urgently needed.
This emerging focus on Lp(a) could not only lead to substantial financial gains—projected sales could reach $5.6 billion annually by 2032—but also save countless lives by preventing heart attacks before they happen.